Comparative Evaluation of β-blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction

Kanorskii, S. G.; Borisenko, Yu.V.

doi:10.18565/cardio.2016.2.24-29

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В отличие от бисопролола ивабрадин существенно повышал толерантность больных к физической нагрузке, качество жизни, снижал уровень NT-proBNP, улучшал эхокардиографические показатели активного расслабления и податливости ЛЖ. Это позволило сделать вывод, что в сравнении с бисопрололом ивабрадин имеет преимущества при лечении больных с ХСН-СФВ на фоне АГ и ишемической болезни сердца [15].…”

Section: клинические семинары §unclassified

“…Пациенты с ХСН-СФВ, участвовавшие в исследовании EDIFY [16] и нашем исследовании [15], значительно различались по многим показателям (см. таблицу 1).…”

Section: клинические семинары §unclassified

“…По сравнению с пациентами в проекте EDIFY участники нашего исследования оказались значительно моложе, имели менее тяжелые проявления диастолической дисфункции ЛЖ. В то же время их отличали неконтролируемая АГ и выраженная гипертрофия ЛЖ, которые поддавались коррекции в течение длительного медикаментозного лечения [15]. Напротив, у больных, включенных в проект EDIFY, по-видимому, имелся обширный фиброз миокарда, рефрактерный к фармакотерапии.…”

Section: клинические семинары §unclassified

See 2 more Smart Citations

Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?

Kanorskiy

Borisenko

2018

CARDIO

View full text Add to dashboard Cite

Хроническая сердечная недостаточность с сохраненной фракцией выброса: возможно ли эффективное лечение? Ключевые слова: сердечная недостаточность с сохраненной фракцией выброса, β-адреноблокаторы, ивабрадин, диастолическая дисфункция левого желудочка.

show abstract

Section: клинические семинары §unclassified

See 1 more Smart Citation

Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?

Kanorskiy

Borisenko

2018

CARDIO

View full text Add to dashboard Cite

show abstract

Ivabradine as adjuvant treatment for chronic heart failure

Benstoem

Kalvelage

Breuer

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Ivabradine in patients with heart failure: a systematic literature review

Khan,

Briere,

Olewinska

et al. 2023

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: Heart failure is a chronic disease linked with significant morbidity and mortality, and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic literature review aimed to assess the efficacy, safety, and patient-reported outcomes (PROs) of ivabradine in patients with heart failure (HF) with reduced ejection fraction (HFrEF) in randomized controlled trials (RCTs) and observational studies. Methods: We searched electronic databases from their inception to July 2021 to include studies that reported on efficacy, safety, or PROs of ivabradine in patients with HFrEF. Results: Of 1947 records screened, 51 RCTs and 6 observational studies were identified. Ivabradine on top of background therapy demonstrated a significant reduction in composite outcomes including hospitalization for HF or cardiovascular death. In addition, observational studies suggested that ivabradine was associated with a significant reduction in mortality. Across all studies, ivabradine use on top of background therapy was associated with greater reductions in heart rate, improved EF, and improved health-related quality of life (QoL) and comparable risk of total adverse events compared to those treated with background therapy alone. Conclusions: Ivabradine on top of background therapy is beneficial for heart rate, hospitalization risk for HF, mortality, EF, and patients’ QoL. Moreover, these benefits were achieved with no significant increase in the overall risk of total adverse events.

show abstract

Comparative Evaluation of β-blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction

Cited by 3 publications

References 0 publications

Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?

Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?

Ivabradine as adjuvant treatment for chronic heart failure

Ivabradine in patients with heart failure: a systematic literature review

Contact Info

Product

Resources

About